|
|
|
Volumn 18, Issue 2, 2005, Pages 59-69
|
|
Consequences of cardiovascular adaptation to spaceflight: implications for the use of pharmacological countermeasures.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;
FLUDROCORTISONE;
MIDODRINE;
SODIUM CHLORIDE;
ADAPTATION;
AEROSPACE MEDICINE;
BLOOD PRESSURE;
BLOOD VOLUME;
CARDIOVASCULAR EFFECT;
COSMONAUT;
DRUG EFFECT;
EXERCISE;
FLIGHT EXPERIMENT;
HEART OUTPUT;
HEART STROKE VOLUME;
HEMODYNAMICS;
HUMAN;
MANNED;
NASA DISCIPLINE CARDIOPULMONARY;
NON-NASA CENTER;
ORTHOSTATIC HYPOTENSION;
PHYSIOLOGY;
REVIEW;
SHORT DURATION;
SPACE FLIGHT;
STS SHUTTLE PROJECT;
VASCULAR RESISTANCE;
WEIGHTLESSNESS;
NASA DISCIPLINE CARDIOPULMONARY;
NON-NASA CENTER;
FLIGHT EXPERIMENT;
MANNED;
SHORT DURATION;
STS SHUTTLE PROJECT;
ADAPTATION, PHYSIOLOGICAL;
ADRENERGIC ALPHA-AGONISTS;
AEROSPACE MEDICINE;
ASTRONAUTS;
BLOOD PRESSURE;
BLOOD VOLUME;
CARDIAC OUTPUT;
CARDIOVASCULAR DECONDITIONING;
EXERCISE;
FLUDROCORTISONE;
HEMODYNAMIC PROCESSES;
HUMANS;
HYPOTENSION, ORTHOSTATIC;
MIDODRINE;
SODIUM CHLORIDE;
SPACE FLIGHT;
STROKE VOLUME;
VASCULAR RESISTANCE;
WEIGHTLESSNESS;
WEIGHTLESSNESS COUNTERMEASURES;
|
|
EID: 26944487318
PISSN: 1089988X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (32)
|
|
References (58)
|
